The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Pharmacotranscriptomics has become a powerful approach for evaluating the therapeutic
efficacy of drugs and discovering new drug targets. Recently, studies of traditional Chinese …

Chimeric antigen receptor (CAR)-T cell-based immunotherapy for cancer and
immunological diseases has made great strides, but it still faces multiple hurdles. Finding …

Vaccination affords protection from disease by activating pathogen-specific immune cells
and facilitating the development of persistent immunologic memory toward the vaccine …

Immunotherapy is emerging as a new treatment modality in breast cancer. After long-
standing use of endocrine therapy and targeted biological therapy, improved understanding …

Treatment of solid tumors with T cell therapy has yielded limited therapeutic benefits to date.
Although T cell therapy in combination with proinflammatory cytokines or immune …

Macrophages are a specialized class of innate immune cells with multifaceted roles in
modulation of the inflammatory response, homeostasis, and wound healing. While …

The efficiency of targeted knock-in for cell therapeutic applications is generally low, and the
scale is limited. In this study, we developed CLASH, a system that enables high-efficiency …

Cancer cells can leverage several cell-intrinsic and-extrinsic mechanisms to escape
immune system recognition. The inherent complexity of the tumor microenvironment, with its …